Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Research Bridge Partners is a venture capital firm that focuses on formative investments in biomedical startup companies. Founded by Isaac Barchas and Reid Hoffman, the firm operates in the United States and aims to bridge the gap between research universities in the mid-continent and commercialization centers in regions like the Bay Area and Boston. This organization targets high-quality investment opportunities that are often overlooked due to limited commercialization resources.
With a commitment to optimizing the value of scientific research, Research Bridge Partners employs proprietary analytics to identify promising academic researchers. The firm collaborates with these researchers to establish the necessary protections and infrastructure for startup success. Currently, the firm is focused on seed-stage investments, utilizing both tax-exempt and for-profit capital to support early-stage startups in the biotech and healthcare sectors.
Research Bridge Partners invests primarily in biomedical startups that are based on breakthroughs from leading researchers at mid-continent universities. Their investment strategy emphasizes the use of proprietary analytics to identify high-quality investment opportunities. The firm collaborates closely with academic researchers to establish the necessary protections and infrastructure for startup success, ensuring that these ventures are well-positioned for commercialization.
Targeting seed-stage investments, Research Bridge Partners develops capitalization strategies tailored to the intellectual property and market conditions of each startup. Their geographic focus is on the United States, specifically in the biotech and healthcare sectors, where they aim to optimize the societal benefits of scientific research through strategic investments.
Lydia McClure, CEO and Board Chair, brings extensive leadership experience in the biotech sector.
Ann Arvin, Director and Senior Vice President of Vir Biotechnology, has a strong background in biomedical research and development.
Lydia Meyer-Turkson, Director and former Head of Public Private Partnerships at Phillips, contributes expertise in partnership development.
Matt Tremblay, Director and CEO of Blackbird Laboratories, has a proven track record in startup management.
Isaac Barchas, Special Advisor and Director, co-founded the firm and has significant experience in venture capital.
Sunil Singhal, Venture Partner, adds depth with his background in healthcare investments.
William Maul Measey, Professor in Surgical Research at UPenn Medicine, provides academic insight into biomedical research.
Jim Graham, Managing Director of Investments, oversees the firm's investment strategies.
Ryan Field, Advisor, offers strategic guidance to portfolio companies.
Maggie Colonnetta, Senior Associate, supports investment analysis and due diligence.
Andrew Cox, Senior Associate, assists in evaluating potential investments.
Gil Cloyd, former CTO at Procter & Gamble and Founding Board Member, brings corporate experience to the team.
Linda Grais, former CEO of Ocera Therapeutics and Founding Board Member, adds her expertise in startup leadership.
Reid Hoffman, Partner at Greylock Partners and Founding Board Member, is a well-known figure in the venture capital community.
What are the investment criteria for Research Bridge Partners?
Research Bridge Partners focuses on seed-stage investments in biomedical startups that are based on breakthroughs from leading researchers at mid-continent universities. They look for high-quality opportunities that may be overlooked due to limited commercialization resources.
How can founders pitch to Research Bridge Partners?
Founders interested in pitching to Research Bridge Partners should prepare a detailed presentation that outlines their startup's unique value proposition, the scientific research backing their innovation, and their commercialization strategy. A clear articulation of the market opportunity and potential impact is essential.
What makes Research Bridge Partners different from other investors?
The firm utilizes proprietary analytics to identify promising academic researchers and collaborates with them to establish necessary protections and infrastructure for startup success. This focus on bridging the gap between research and commercialization sets them apart.
What is the geographic scope of Research Bridge Partners?
Research Bridge Partners primarily invests in the United States, focusing on biomedical startups emerging from mid-continent universities.
What type of support do they provide to portfolio companies?
Research Bridge Partners collaborates with founders to develop capitalization strategies and provides access to necessary resources and networks to enhance the chances of startup success.
What is the typical check size for investments?
While specific check sizes are not disclosed, Research Bridge Partners focuses on seed-stage investments, which typically range from hundreds of thousands to a few million dollars.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.